Biopharmaceutical Switching in Psoriasis Treatment
For adults with plaque psoriasis who fail a biologic, switching—especially across classes—can yield high PASI responses without an observed increase...
Clinical insightReview evidence by treatment modality: IL-17 Inhibitor — concise summaries and practical next steps.
For adults with plaque psoriasis who fail a biologic, switching—especially across classes—can yield high PASI responses without an observed increase...
Clinical insightIn older adults with psoriatic disease, IL‑12/23/17 biologics were associated with fewer serious infections, while tofacitinib was associated with...
Clinical insightFewer than 60% of patients starting systemic immunomodulators received recommended baseline tests. Clinicians should verify TB and hepatitis...
Clinical insightParadoxical eczema was rare in biologic-treated psoriasis, with the lowest observed risk on IL‑23 inhibitors. Screen for personal history of atopic...
Clinical insightYou're all caught up!
You've explored 4 papers
Check back later for more research